Evaluation of the highly sensitized transplant recipient.
The immune response against alloantigens involves the production of antibodies and development of T-cell immunity. Recipients sensitized to HLA antigens may have antibodies to almost all donors and may not be able to find a suitable kidney transplant donor. Strategies available to enable these patients to obtain a transplant are to give priority to highly sensitized patients, to perform therapy for antibody reduction or to transplant with existing antibodies and to intervene as needed with post-transplant treatment. While sensitization against HLA antigens is the most important cause of immunological transplant failure, other types of alloantigens, many of them expressed selectively in endothelial cells, and autoantigens may also be involved. Molecular typing and solid-phase antibody testing have markedly changed this field in the last few years. Methods for the analysis of HLA antibodies and for the study of T-cell reactivity and sensitization will also be discussed. Virtual cross-matching can now be performed for many patients, resulting in considerable savings in time and effort. Successful application of this approach requires the intervention of highly trained personnel with a good understanding of the limitations of the procedure and with intimate knowledge of the antibody profiles of the patients on the waiting list.
Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd. - G4.212, Dallas, TX 75390-8886, USA. peter.stastny@utsouthwestern.edu
Peter
P
Stastny
Ian-Michael
IM
Salvador
Bhavna
B
Lavingia
D003888:Desensitization, Immunologic / Q000379:methods*; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D008297:Male; D014181:Transplantation Immunology / Q000276:immunology*
D006680:HLA Antigens
J Exp Med. 1968 Oct 1;128(4):623-37
5675436
N Engl J Med. 1969 Apr 3;280(14):735-9
4886455
Transpl Int. 2002 Nov;15(11):563-9
12461661
Am J Transplant. 2009 Nov;9(11):2532-41
19843031
Am J Transplant. 2010 Jan;10(1):26-9
19958328
J Heart Lung Transplant. 2008 Aug;27(8):817-22
18656792
Transplantation. 2010 Apr 27;89(8):962-7
20075791
J Am Soc Nephrol. 2003 May;14(5):1336-48
12707403
Hum Immunol. 2005 Sep;66(9):989-97
16360839
Br J Dermatol. 1996 May;134(5):848-54
8736324
Am J Transplant. 2005 Sep;5(9):2265-72
16095508
J Clin Invest. 1977 Aug;60(2):449-54
874103
J Am Soc Nephrol. 2001 Dec;12(12):2807-2814
11729251
Lancet. 1966 Sep 24;2(7465):662-5
4162350
Contrib Nephrol. 2009;162:1-12
19001809
Transplantation. 1982 Dec;34(6):360-6
6760495
Transplantation. 2010 Jul 27;90(2):113-20
20531074
Angiogenesis. 2009;12(1):91-100
19225898
Transplantation. 2009 Aug 27;88(4):568-74
19696641
Clin Immunol. 2000 Oct;97(1):50-8
10998317
Lancet. 2005 Apr 30-May 6;365(9470):1570-6
15866311
Transplantation. 1975 Apr;19(4):286-90
1080302
Tissue Antigens. 2008 Jan;71(1):1-15
18096006
Transplantation. 2003 Jan 15;75(1):43-9
12544869
Transplant Proc. 2000 Dec;32(8):2745-6
11134783
Tissue Antigens. 1975 May;5(4):280-5
50635
J Am Soc Nephrol. 2010 Aug;21(8):1398-406
20634297
Transplantation. 2007 Sep 27;84(6):738-45
17893607